Literature DB >> 15306158

Role of the endocannabinoid system in Alzheimer's disease: new perspectives.

M R Pazos1, E Núñez, C Benito, R M Tolón, J Romero.   

Abstract

The role of the endocannabinoid system in several diseases is currently under intense study. Among these, Alzheimer's disease may be a new promising area of research. We have recently reported the existence of profound changes in the location and density of several elements of this system in Alzheimer's disease tissue samples, indicating that a non-neuronal endocannabinoid system is up-regulated in activated glia. Additional data from other groups suggest that glial cells may be important elements in the regulation of endocannabinoid system activity, both in health as in disease. Some of these aspects are briefly discussed in the present review.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15306158     DOI： 10.1016/j.lfs.2004.03.026

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  13 in total

1.  A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis.

Authors:  Cristina Benito; Woong-Ki Kim; Wong-Ki Kim; Iván Chavarría; Ceceila J Hillard; Ken Mackie; Rosa M Tolón; Kenneth Williams; Ken Williams; Julián Romero
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

2.  Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands.

Authors:  Q-R Liu; C-H Pan; A Hishimoto; C-Y Li; Z-X Xi; A Llorente-Berzal; M-P Viveros; H Ishiguro; T Arinami; E S Onaivi; G R Uhl
Journal:  Genes Brain Behav       Date:  2009-06-03       Impact factor: 3.449

Review 3.  Alternatives to atypical antipsychotics for the management of dementia-related agitation.

Authors:  Michael J Passmore; David M Gardner; Yvette Polak; Kiran Rabheru
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 4.  Brain cannabinoid receptor 2: expression, function and modulation.

Authors:  De-Jie Chen; Ming Gao; Fen-Fei Gao; Quan-Xi Su; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2017-01-09       Impact factor: 6.150

5.  A molecular link between the active component of marijuana and Alzheimer's disease pathology.

Authors:  Lisa M Eubanks; Claude J Rogers; Albert E Beuscher; George F Koob; Arthur J Olson; Tobin J Dickerson; Kim D Janda
Journal:  Mol Pharm       Date:  2006 Nov-Dec       Impact factor: 4.939

Review 6.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

Review 7.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 8.  Alzheimer's disease; taking the edge off with cannabinoids?

Authors:  V A Campbell; A Gowran
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

9.  Molecules Acting on CB1 Receptor and their Effects on Morphine Withdrawal In Vitro.

Authors:  Anna Capasso; Chiara Gallo
Journal:  Open Biochem J       Date:  2009-12-11

10.  N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties.

Authors:  Garry Milman; Yehoshua Maor; Saleh Abu-Lafi; Michal Horowitz; Ruth Gallily; Sandor Batkai; Fong-Ming Mo; Laszlo Offertaler; Pal Pacher; George Kunos; Raphael Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-07       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.